Komen Scholar Event

Patient-Derived Models of Breast Cancer Metastasis and Treatment Response

Presenting: Dr. Alana Welm, Komen Scholar
November 8, 2018, at the UNT Health Science Center

Researcher Alana Welm, a professor at Huntsman Cancer Institute has discovered a new way by which breast cancer metastasis works, and how to stop it. She will be in Fort Worth on November 8, 2018, to speak on metastatic breast cancer.

First Session for Health Care Providers at 7:30 am – 8:30 am.
See the INCEDO site for complete continuing education accreditation information:

UNT Health Science Center
MET Building / Room 109-111
Parking available at Lots 7 & 19 (UNTHSC Campus Map)


Brunch Second Session at 9 am – 10:30 am
UNT Health Science Center
MET Building / Room 109-111
Parking available at Lots 7 & 19 (UNTHSC Campus Map)


Alana Welm, PhD, is an Associate Professor in the Department of Oncological Sciences at the University of Utah, an Investigator at the Huntsman Cancer Institute, and Co-Leader of the Cell Response and Regulation Program at HCI. Welm’s laboratory studies breast cancer metastasis.

Dr. Welm completed her PhD in Cell and Molecular Biology at Baylor College of Medicine in Houston, TX under the supervision of Gretchen Darlington, PhD. She then went on to conduct postdoctoral training in Dr. J. Michael Bishop’s laboratory at the University of California, San Francisco where her work focused on developing new models of breast cancer metastasis. Dr. Welm started her laboratory at the University of Utah’s Huntsman Cancer Institute in 2007, and was promoted to Associate Professor with tenure in 2013.

The research in Dr. Welm’s laboratory is focused on solving the problem of breast cancer metastasis using in vivo modeling of mouse and human breast cancers. Dr. Welm’s group discovered that the Ron kinase pathway is an important facilitator of breast cancer metastasis through its unique dual function in tumor cells and in resident macrophages. Current areas of research include (1) pre-clinical studies of various Ron inhibitors for treatment and prevention of metastatic breast cancer; (2) pre-clinical and early clinical studies of Ron/Met inhibitors in bone metastatic cancers; (3) discovering molecular mechanisms by which Ron kinases promote metastasis through cell-autonomous and non cell-autonomous pathways; and (4) refining “precision medicine” for metastatic breast cancer using functional assays in patient-derived breast tumor grafts.


Presented By

William E. Scott Foundation

UNTHSC Foundation



Go to Top